APOQUEL® 16 MG Tablet

Manufacturer/Marketer: Zoetis / Zoetis India Limited
Generic Name: Oclacitinib
Product Type: Veterinary Prescription Medicine
Therapeutic Category: Janus Kinase (JAK) Inhibitor / Antipruritic / Immunomodulator
Target Species: Dogs only
Dosage Form: Oral tablet
Strength: 16 mg Oclacitinib per tablet
Route: Oral
Prescription Status: Veterinary prescription medicine. 

Composition

Each APOQUEL 16 mg Tablet contains:

Oclacitinib – 16 mg
(as Oclacitinib Maleate)

Oclacitinib is a synthetic Janus kinase (JAK) inhibitor that modulates cytokine signalling involved in allergic inflammation and itching. 

Clinical Description

APOQUEL is a targeted anti-itch veterinary medicine for dogs. By inhibiting JAK-dependent cytokine signalling involved in pruritus and allergic inflammation, it helps control itching associated with allergic skin disease without being a corticosteroid. 

Indications

APOQUEL is indicated in dogs 12 months of age or older for:

• Pruritus associated with allergic dermatitis
• Atopic dermatitis
• Allergic itching, redness and associated skin inflammation. 

Dosage & Administration

The recommended dose is 0.4–0.6 mg oclacitinib/kg body weight orally, twice daily for up to 14 days, followed by the same dose once daily for maintenance, when continued treatment is considered appropriate by the veterinarian. It may be administered with or without food. 

For the 16 mg tablet, the official dosing chart is:

Dogs in the intervening weight ranges may require another tablet strength or combination to achieve the recommended dose. 

Key Benefits

APOQUEL provides targeted control of allergic itching and atopic dermatitis, helping reduce scratching and associated skin irritation. It can be administered with or without food and is suitable for veterinarian-directed maintenance treatment when ongoing control is required. 

Contraindications & Precautions

Do not use in dogs under 12 months of age. It should not be used in dogs with serious infections. Because oclacitinib modulates immune function, it can increase susceptibility to infections and may worsen existing parasitic skin infestations or pre-existing neoplastic conditions. 

It is also not recommended for breeding, pregnant or lactating dogs. Long-term therapy should be periodically reviewed by a veterinarian. 

Possible Adverse Effects

Reported adverse effects can include vomiting and diarrhoea. Because of its immunomodulatory action, infections and other clinically important changes should be monitored during treatment, particularly with prolonged use. 

Withdrawal Period

Not applicable, because APOQUEL is indicated for dogs, not food-producing animals. 

Storage

Store below 30°C, protected from inappropriate heat and moisture, and keep out of reach of children and animals. 

Important Warning

FOR ANIMAL TREATMENT ONLY – DOGS ONLY.

APOQUEL is a prescription immunomodulatory medicine. It should be administered under veterinary supervision, particularly during long-term therapy. Persistent skin disease should also be evaluated for underlying causes such as ectoparasites, infection, food allergy or environmental allergens.

Rayavets Short Description

APOQUEL 16 MG Tablet by Zoetis contains Oclacitinib 16 mg and is a veterinary JAK inhibitor used in dogs 12 months and older for control of pruritus associated with allergic dermatitis and atopic dermatitis. Recommended oclacitinib dosage is 0.4–0.6 mg/kg orally twice daily for up to 14 days, followed by once-daily maintenance as directed by the veterinarian. It may be given with or without food. For dogs only; veterinary prescription use.